Aggressive Posterior Retinopathy of Prematurity: Long-Term Outcomes Following Intravitreal Bevacizumab

被引:3
|
作者
Naravane, Ameay V. [1 ]
Belin, Peter J. [2 ]
Rubino, Shaina [3 ]
Quiram, Polly A. [2 ]
机构
[1] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN USA
[2] Vitreo Retinal Surg, Phys Associates, Minneapolis, MN 55404 USA
[3] North Carolina Retina Associates, Chapel Hill, NC USA
来源
FRONTIERS IN PEDIATRICS | 2022年 / 10卷
关键词
aggressive posterior retinopathy of prematurity; APROP; bevicizumab; intravitreal injection; laser; premature (babies); neurodevelopmental outcomes; ophthalmic outcomes; NEURODEVELOPMENTAL OUTCOMES; LASER; VEGF; PHOTOCOAGULATION; THERAPY;
D O I
10.3389/fped.2022.778585
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
PurposeThe purpose of this study is to review the neonatal and early childhood course of children who were treated with intravitreal bevacizumab for APROP and identify any long term limitations these children face years after treatment. MethodsThis retrospective consecutive case series reviewed both ophthalmologic and pediatric medical records to determine ocular and neurologic function following treatment with a single injection of intravitreal bevacizumab (IVB) for APROP. Patient records were reviewed to identify the gestational age, average birth weight, gender, post-menstrual age (PMA) at the time of injection, regression status, rescue therapy events, final visual acuity, final refraction, ophthalmologic diagnoses and complications, neurologic diagnoses, and duration of follow up. ResultsThe study included 43 eyes from 13 male and 9 female children. The average gestational age was 24 weeks and average birth weight was 625.2 grams. The average follow-up was 4.08 years (range: 1.85-7.36 years). The average PMA at time of bevacizumab injection was 35.59 weeks. Thirty-five eyes eventually received laser photocoagulation at an average PMA of 53.17 weeks. All eyes in this study demonstrated regression without progression to retinal detachment. At last follow up, 67% (29/43) of eyes were able to discern letters or shapes, with an average visual acuity of 20/37. 16 (72%) children were diagnosed with perinatal neurological disorders. 59% (n = 13) developed chronic neurological impairment, 77% (n = 10) of whom developed neurodevelopmental delay. Several infants were diagnosed with endocrine disease or genetic syndromes. ConclusionsExtreme prematurity is associated with significant morbidity. Nearly all infants (92%) who developed chronic neurologic disease were diagnosed with neurologic disease during the perinatal period. Intravitreal bevacizumab, often with adjuvant photocoagulation, led to regression without detachment in 100% of eyes, with most verbal children retaining functional vision.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Aggressive Posterior Retinopathy Of Prematurity: Functional Outcomes Following Intravitreal Bevacizumab
    Rubino, Shaina
    Quiram, Polly
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [2] Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity
    Travassos, Antonio
    Teixeira, Susana
    Ferreira, Pinto
    Regadas, Isaura
    Travassos, Ana Sofia
    Esteves Esperancinha, Florindo
    Prieto, Isabel
    Pires, Graca
    Van Velze, Robert
    Valido, A.
    do Ceu Machado, Maria
    [J]. OPHTHALMIC SURGERY LASERS & IMAGING, 2007, 38 (03) : 233 - 237
  • [3] Long-Term Safety and Efficacy of Intravitreal Bevacizumab (IVB) for Aggressive Posterior Retinopathy of Prematurity (AP-ROP)
    Malhotra, Pankaj
    Kishore, Kamal
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [4] Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity
    Gunay, Murat
    Celik, Gokhan
    Gunay, Betul Onal
    Aktas, Alev
    Karatekin, Guner
    Ovali, Fahri
    [J]. ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2015, 78 (05) : 300 - 304
  • [5] Long-term retinal vasculature abnormalities following intravitreal bevacizumab for retinopathy of prematurity
    Sternfeld, Amir
    Rahmani, Safa
    Rossen, Jennifer L.
    Zhang, David L.
    Li, Yuping D.
    Quan, Victor L.
    Huang, Russell
    Yoon, Hawke H.
    [J]. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 260 (06) : 1915 - 1921
  • [6] Long-term retinal vasculature abnormalities following intravitreal bevacizumab for retinopathy of prematurity
    Amir Sternfeld
    Safa Rahmani
    Jennifer L. Rossen
    David L. Zhang
    Yuping D. Li
    Victor L. Quan
    Russell Huang
    Hawke H. Yoon
    [J]. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260 : 1915 - 1921
  • [7] Rescue Intravitreal Bevacizumab (Avastin) for Aggressive Posterior Retinopathy of Prematurity
    Qureshi, Farhan
    Dewhurst, Christopher
    Yoxall, C. W.
    Clark, David
    [J]. SEMINARS IN OPHTHALMOLOGY, 2011, 26 (02) : 55 - 58
  • [8] Long-term observation of the treatment of laser photocoagulation versus intravitreal bevacizumab in identical twins with aggressive posterior retinopathy of prematurity
    Jeon, Seung Hee
    Roh, Young Jung
    [J]. ACTA OPHTHALMOLOGICA, 2019, 97
  • [9] Intravitreal bevacizumab injection in aggressive posterior retinopathy of prematurity compared with type I retinopathy of prematurity
    Amir Eftekhari Milani
    Narges Hassanpoor
    Mohammadreza Mousavi Mirkala
    Arash Taheri
    Ali Golizade
    Mohamad Reza Niyousha
    [J]. International Ophthalmology, 2020, 40 : 477 - 482
  • [10] Intravitreal bevacizumab injection in aggressive posterior retinopathy of prematurity compared with type I retinopathy of prematurity
    Milani, Amir Eftekhari
    Hassanpoor, Narges
    Mirkala, Mohammadreza Mousavi
    Taheri, Arash
    Golizade, Ali
    Niyousha, Mohamad Reza
    [J]. INTERNATIONAL OPHTHALMOLOGY, 2020, 40 (02) : 477 - 482